XLV is trading 3.22% up now at $176.10 after broad healthcare-sector buying and renewed institutional rotation into defensive growth, following upgraded S&P 500 healthcare earnings forecasts.
- Improving regulatory conditions, FDA approval momentum, and increased M&A activity are supporting the sector.
- Positive Moderna-Merck melanoma vaccine results added biotechnology enthusiasm, while technology and AI-stock weakness encouraged sector rotation.
- Reuters previously described improving earnings, dealmaking, and valuations as drivers of healthcare’s rebound.